Literature DB >> 10480340

Chemosensitivity of glioma cells in vitro: a meta analysis.

J E Wolff1, T Trilling, G Mölenkamp, R M Egeler, H Jürgens.   

Abstract

PURPOSE: The disappointing results of chemotherapy in glioblastoma might be caused by the choices of agents, which mostly include nitrosurea. We compared the in vitro efficacy of chemotherapeutic agents, developing a method to summarize published data.
METHOD: Between 1966 and 1995 chemotherapy in glioma cells was reported in 1643 articles. Efficacy was mostly described by the drug concentration that killed 50% of the cells (LC50). It was measured with various cell-culture techniques, of which a colorimetric test [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide] was mostly used. We calculated factors from these data to transform results to LC50 values as if the colorimetric test was used in all of them. This allowed data from all publications to be summarized in a new type of meta analysis.
RESULTS: The most important agents and the average LC50 values (mg/l) were actinomycin-D 0.042, vincristine 0.075, mitoxantrone 0.12, vinblastine 0.21, doxorubicin 0.29, diaziquone 0.76, cisplatin 1.1, methotrexate 1.1, cytasine arabinoside 1.59, 5-flurouracil 2.33, bleomycin 18.6, carboplatin 29.8, carmustine 37.0, nimustine 48.9, and lomustine 76.7. The most resistant cell was SNB56, followed with increasing sensitivity by SF128 and A172, and primary cultures P497, SF210, U87MG, SF126, 9L, P540, U251MG, HU62, C6. The complete list of original data is available upon request.
CONCLUSION: The efficacy of nitrosourea in vitro is low.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480340     DOI: 10.1007/s004320050305

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  50 in total

1.  Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

Authors:  A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

2.  Which therapy works better in choroid plexus carcinomas?

Authors:  Su G Berrak; Diane D Liu; Brigitte Wrede; Johannes E Wolff
Journal:  J Neurooncol       Date:  2010-10-26       Impact factor: 4.130

3.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.

Authors:  Keith L Black; Dali Yin; John M Ong; Jinwei Hu; Bindu M Konda; Xiao Wang; MinHee K Ko; Jennifer-Ann Bayan; Manuel R Sacapano; Andreas Espinoza; Dwain K Irvin; Yan Shu
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

4.  HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  Genglin Jin; Stephen Cook; Bo Cui; William C Chen; Stephen T Keir; Patrick Killela; Chunhui Di; Cathy A Payne; Simon G Gregory; Roger McLendon; Darell D Bigner; Hai Yan
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

5.  Altered expression of long non-coding RNAs during genotoxic stress-induced cell death in human glioma cells.

Authors:  Qian Liu; Shanquan Sun; Wei Yu; Jin Jiang; Fei Zhuo; Guoping Qiu; Shiye Xu; Xuli Jiang
Journal:  J Neurooncol       Date:  2015-02-03       Impact factor: 4.130

6.  Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

Authors:  Marco Saini; Florian Roser; Samii Hussein; Madjid Samii; Mattia Bellinzona
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.

Authors:  Preethi Prasad; Hernan Vasquez; Chandra M Das; Vidya Gopalakrishnan; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2008-10-14       Impact factor: 4.130

8.  Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.

Authors:  Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

9.  Doxorubicin-mediated apoptosis in glioma cells requires NFAT3.

Authors:  Sreelatha Gopinath; Sravan K Vanamala; Meena Gujrati; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  Cell Mol Life Sci       Date:  2009-09-27       Impact factor: 9.261

10.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.